Showing results (131-140 of 259) with videos related to
Sort By:
Pageof 26
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I TrialKenneth S Thress, Vivien Jacobs, Helen K Angell, et al.The Oncologist|August 5, 2015
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in AsiaHung-Yang Kuo, Zhong-Zhe Lin, Raymond Kuo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2019
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief ReportJames Chih-Hsin Yang, Frances A Shepherd, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker AnalysisJames Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, et al.International Journal of Cancer|November 29, 2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutationsYen-Ting Lin, Jin-Shing Chen, Wei-Yu Liao, et al.Lung Cancer (Amsterdam, Netherlands)|November 5, 2013
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopyTzu-Hsiu Tsai, Ching-Yao Yang, Chao-Chi Ho, et al.Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysisLi-Yang Chen, Miguel A Molina-Vila, Sheng-Yuan Ruan, et al.Investigational New Drugs|March 3, 2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJih-Hsiang Lee, Tom Wei-Wu Chen, Chih-Hung Hsu, et al.Pageof 26